Tandem Diabetes Care Inc. bulls still see upside for the insulin pump maker, even after shares increased ten-fold so far this year. Sell-side analysts rushed to boost their price targets for one of the Russell 2000 Index’s best performers in the wake of last week’s Food and Drug Administration approval of a technology for the company’s insulin pump. Piper Jaffray analyst JP McKim called the approval a “game changer” that will help attract patients and give them reason to upgrade to newer pumps. …read more
Source:: Yahoo Finance
